Inspire Medical Systems Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-7.0%projected annual EPS growth
Analyst Coverage
15analysts covering
FY EPS (est.)
$1.25next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly204.6MTarget: 825000000 to 875000000 (Full Year 2026 Guidance)
Total Cash, Cash Equivalents, and Investments Quarterly399.7MTarget: Maintain robust liquidity with zero debt
ADHERE Registry Patient Enrollment AnnuallyTarget: Transition to ADHERE 2.0 as part of Inspire SleepSync in the U.S.
Watch Items
- Medicare Reimbursement and Coding UncertaintyTrigger: Transition from CPT code 64568 to 64582 and implementation of the WISeR programAction: Provide center-by-center physician education, monitor prior authorization submission rates, and track progress of the new C-code for Inspire V procedures.
- Inspire V System Commercial RolloutTrigger: Transition from limited market release to full commercial launchAction: Monitor implant times, device revision rates, and patient adherence metrics to ensure clinical efficacy and operational efficiency.
- Competitive Threats from Alternative TherapiesTrigger: Market entry of Nyxoah's UAS platform and adoption of GLP-1 weight-loss therapiesAction: Leverage IP litigation successes, highlight long-term cardiovascular outcomes data, and position GLP-1s as a potential funnel to expand the addressable market.
Research as of 19 Jun 2026